IN2012DN01641A - - Google Patents
Download PDFInfo
- Publication number
- IN2012DN01641A IN2012DN01641A IN1641DEN2012A IN2012DN01641A IN 2012DN01641 A IN2012DN01641 A IN 2012DN01641A IN 1641DEN2012 A IN1641DEN2012 A IN 1641DEN2012A IN 2012DN01641 A IN2012DN01641 A IN 2012DN01641A
- Authority
- IN
- India
- Prior art keywords
- compounds
- pentoxifylline
- derivatives
- relates
- novel
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 abstract 4
- LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical class O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 abstract 2
- BYPFEZZEUUWMEJ-UHFFFAOYSA-N Pentoxifylline Chemical class O=C1N(CCCCC(=O)C)C(=O)N(C)C2=C1N(C)C=N2 BYPFEZZEUUWMEJ-UHFFFAOYSA-N 0.000 abstract 2
- 229940083747 low-ceiling diuretics xanthine derivative Drugs 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 230000009286 beneficial effect Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 229960001476 pentoxifylline Drugs 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
- C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
- C07D473/10—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3 with methyl radicals in positions 3 and 7, e.g. theobromine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
- C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Urology & Nephrology (AREA)
- Endocrinology (AREA)
- Immunology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Virology (AREA)
- Oncology (AREA)
- Child & Adolescent Psychology (AREA)
- Ophthalmology & Optometry (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Molecular Biology (AREA)
- Emergency Medicine (AREA)
- Communicable Diseases (AREA)
- Vascular Medicine (AREA)
- Toxicology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Dermatology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pain & Pain Management (AREA)
Abstract
This invention relates to novel compounds that are substituted xanthine derivatives and pharmaceutically acceptable salts thereof. For example, this invention relates to novel substituted xanthine derivatives that are derivatives of pentoxifylline. This invention also provides compositions comprising one or more compounds of this invention and a carrier and the use of the disclosed compounds and compositions in methods of treating diseases and conditions for which pentoxifylline and related compounds are beneficial.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US23934209P | 2009-09-02 | 2009-09-02 | |
US12/873,991 US20110053961A1 (en) | 2009-02-27 | 2010-09-01 | Substituted xanthine derivatives |
PCT/US2010/047708 WO2011028922A1 (en) | 2009-09-02 | 2010-09-02 | Substituted xanthine derivatives |
Publications (1)
Publication Number | Publication Date |
---|---|
IN2012DN01641A true IN2012DN01641A (en) | 2015-06-05 |
Family
ID=43625765
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IN1641DEN2012 IN2012DN01641A (en) | 2009-09-02 | 2010-09-02 |
Country Status (22)
Country | Link |
---|---|
US (1) | US20110053961A1 (en) |
EP (2) | EP2473053B1 (en) |
JP (1) | JP5292516B2 (en) |
KR (1) | KR101591137B1 (en) |
CN (2) | CN102480968B (en) |
AU (1) | AU2010289465B2 (en) |
BR (1) | BR112012008108B1 (en) |
CA (1) | CA2771123C (en) |
DK (1) | DK2473053T3 (en) |
EA (1) | EA023809B1 (en) |
ES (1) | ES2542401T3 (en) |
HR (1) | HRP20150797T1 (en) |
HU (1) | HUE026800T2 (en) |
IN (1) | IN2012DN01641A (en) |
ME (1) | ME02177B (en) |
MX (1) | MX2012002705A (en) |
PH (1) | PH12012500278A1 (en) |
PL (1) | PL2473053T3 (en) |
PT (1) | PT2473053E (en) |
SI (1) | SI2473053T1 (en) |
WO (1) | WO2011028922A1 (en) |
ZA (1) | ZA201201295B (en) |
Families Citing this family (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP5292413B2 (en) * | 2008-02-29 | 2013-09-18 | コンサート ファーマシューティカルズ インコーポレイテッド | Substituted xanthine derivatives |
WO2010075086A2 (en) * | 2008-12-15 | 2010-07-01 | Auspex Pharmaceuticals, Inc. | Pyrrolidinone inhibitors of pde-4 |
US8263601B2 (en) | 2009-02-27 | 2012-09-11 | Concert Pharmaceuticals, Inc. | Deuterium substituted xanthine derivatives |
AU2010289551A1 (en) * | 2009-09-02 | 2012-03-01 | Concert Pharmaceuticals, Inc. | Substituted xanthine derivatives |
US9260432B2 (en) | 2009-09-02 | 2016-02-16 | Concert Pharmaceuticals, Inc. | Substituted derivatives of bicyclic [4.3.0] heteroaryl compounds |
US9074233B2 (en) | 2010-09-01 | 2015-07-07 | Concert Pharmaceuticals, Inc. | Process for preparing an enantiomerically enriched, deuterated secondary alcohol from a corresponding ketone without reducing deuterium incorporation |
US20130324564A1 (en) * | 2010-09-01 | 2013-12-05 | Concert Pharmaceuticals, Inc. | Polymorphs of (s)-1-(4,4,6,6,6-pentadeutero-5-hydroxyhexyl)-3-7-dimethyl-1h-purine-2,6(3h,7h)-dione |
WO2012031072A1 (en) | 2010-09-01 | 2012-03-08 | Concert Pharmaceuticals, Inc. | Process for preparing an enantiomerically enriched, deuterated secondary alcohol from a corresponding ketone without reducing deuterium incorporation |
EA201491878A8 (en) | 2012-04-13 | 2015-02-27 | Концерт Фармасьютикалс, Инк. | SUBSTITUTED XANTHINE DERIVATIVES |
WO2013159006A1 (en) * | 2012-04-20 | 2013-10-24 | Concert Pharmaceuticals, Inc. | Polymorphs of (s)-1-(4,4,6,6,6-pentadeutero-5-hydroxyhexyl)-3,7-dimethyl-1h-purine-2,6(3h,7h)-dione |
CA2981791A1 (en) * | 2014-04-18 | 2015-10-22 | Concert Pharmaceuticals, Inc. | Methods of treating hyperglycemia |
WO2015175008A1 (en) * | 2014-05-14 | 2015-11-19 | Concert Pharmaceuticals, Inc. | Methods of treating chronic kidney disease characterized by macroalbuminuria |
WO2015184248A1 (en) * | 2014-05-30 | 2015-12-03 | Concert Pharmaceuticals, Inc. | Methods of treating fibrotic diseases |
CN105566324B (en) * | 2014-10-09 | 2020-04-03 | 广东众生睿创生物科技有限公司 | Hydroxypurine compounds and their applications |
KR101997592B1 (en) * | 2014-10-09 | 2019-07-08 | 광동 쫑성 파마세티컬 컴패니, 리미티드 | Hydroxyl purine compounds and applications thereof |
WO2016184312A1 (en) * | 2015-05-20 | 2016-11-24 | 南京明德新药研发股份有限公司 | Hydroxyl purine compounds and use thereof |
WO2017079003A1 (en) * | 2015-11-03 | 2017-05-11 | NeuForm Pharmaceuticals, Inc. | Deuterated compounds for treating blood cancers, and compositions and methods thereof |
CN108699061B (en) * | 2015-11-16 | 2022-07-05 | 纽弗姆制药有限公司 | Deuterated compounds for the treatment of hematological malignancies, inflammation and autoimmune diseases |
CA3155338A1 (en) * | 2019-09-25 | 2021-04-01 | Goldfinch Bio, Inc. | Xanthine cb1 inhibitors |
CN111440041B (en) * | 2020-05-19 | 2021-03-05 | 北京理工大学 | A kind of synthetic method of toluene-d8 |
CN114380829A (en) * | 2021-12-28 | 2022-04-22 | 赤峰万泽药业股份有限公司 | A kind of pentoxifylline and its synthetic method and application |
WO2024199096A1 (en) * | 2023-03-24 | 2024-10-03 | 陕西麦科奥特科技有限公司 | Anticoagulation reversal agent, and preparation method therefor and use thereof |
Family Cites Families (68)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BE793059A (en) | 1972-02-28 | 1973-04-16 | Ritzerfeld Gerhard | INCHING DEVICE FOR ROTARY PRESSES A |
JPS5632477B2 (en) | 1973-03-07 | 1981-07-28 | ||
DE2330742C2 (en) | 1973-06-16 | 1982-07-29 | Hoechst Ag, 6000 Frankfurt | 1- (Oxoalkyl) -3-methyl-7-alkylxanthines, process for their preparation and pharmaceuticals containing them |
JPS5610188B2 (en) | 1973-09-14 | 1981-03-06 | ||
JPS5756481B2 (en) | 1974-06-13 | 1982-11-30 | ||
CA1037234A (en) | 1976-06-01 | 1978-08-29 | Aluma Building Systems Incorporated | Wall forming structure for poured concrete walls |
FR2376188A1 (en) | 1976-12-28 | 1978-07-28 | Elf Union | PROCESS FOR PREPARING COMPOSITIONS OF POLYMERIC BITUMES |
JPS54120627A (en) | 1978-03-13 | 1979-09-19 | Nittetsu Kakoki Kk | Regenaration of asphalt concrete |
JPS5576876A (en) | 1978-12-05 | 1980-06-10 | Grelan Pharmaceut Co Ltd | Preparation of 1-(oxoalkyl)-3,7-dimethylxanthine derivatne |
JPS5581055A (en) | 1978-12-12 | 1980-06-18 | Kubota Ltd | Drawing device of pipe |
JPS55122779A (en) | 1979-03-13 | 1980-09-20 | Maruko Seiyaku Kk | Preparation of theobromine derivative |
CS201558B1 (en) | 1979-05-14 | 1980-11-28 | Pavol Kovar | Method of preparing 1-/5-oxohexyl/-3,7-dimethylxanthine |
JPS5677279A (en) | 1979-11-28 | 1981-06-25 | Ota Seiyaku Kk | Preparation of xanthine derivative |
JPS56125451A (en) | 1980-03-08 | 1981-10-01 | Mitsubishi Gas Chem Co Inc | Production of modified asphalt |
JPS5762278A (en) | 1980-10-01 | 1982-04-15 | Sagami Chem Res Center | Theobromine derivative and its preparation |
JPS5780385A (en) | 1980-11-05 | 1982-05-19 | Mitsubishi Petrochem Co Ltd | Preparation of 1-((omega-1)-oxoalkyl)-3,7-dialkylxanthine |
JPS5785387A (en) | 1980-11-14 | 1982-05-28 | Teikoku Chem Ind Corp Ltd | Preparation of 1-(-5'-oxohexyl)-3,7-dimethylxanthine |
JPS5798284A (en) | 1980-12-10 | 1982-06-18 | Kawashima Yakuhin Kaihatsu Kk | Preparation of 1-(5-oxohexyl)-3,7-dimethylxanthine |
JPS5838284B2 (en) | 1981-04-14 | 1983-08-22 | ミサワホ−ム株式会社 | Demolding equipment |
JPS57200391A (en) | 1981-06-02 | 1982-12-08 | Daito Koeki Kk | 1-(5-oxo-2-hexenyl)3,7-dimethylxanthine |
JPS58134092A (en) | 1982-02-05 | 1983-08-10 | Sagami Chem Res Center | Theobromine derivative |
JPS58150594A (en) | 1982-03-03 | 1983-09-07 | Daito Koeki Kk | Preparation of xanthine derivative |
CS237719B1 (en) | 1983-05-12 | 1985-10-16 | Jan Jendrichovsky | Preparation method of dimethyl-(5-oxohexyl)-xanthine |
DE3508097A1 (en) | 1984-07-21 | 1986-02-06 | Hoechst Ag, 6230 Frankfurt | COMBINATION PRODUCT MADE OF XANTHINE DERIVATIVES AND O-ACETYLSALICYL ACID OR THEIR PHARMACOLOGICALLY COMPATIBLE SALTS AND THE USE THEREOF |
DD274334A3 (en) | 1985-12-17 | 1989-12-20 | Dresden Arzneimittel | PROCESS FOR PREPARING PURE 3,7-DIMETHYL-1- (5-OXOHEXYL) -XANTHINE |
IL100533A (en) | 1986-12-31 | 1994-05-30 | Hoechst Roussel Pharma | Pharmaceutical compositions containing xanthine derivatives for treating hiv and related disease states |
CS263595B1 (en) | 1988-01-06 | 1989-04-14 | Rybar Alfonz | Process for preparing 7-n-propyl-3-methyl-3,7-dihydro-1h-purin-2,6-dione |
JP2661666B2 (en) | 1988-02-19 | 1997-10-08 | ヘキスト薬品工業株式会社 | Anti-peptic ulcer agent |
IT1231779B (en) | 1989-08-09 | 1991-12-21 | Eniricerche Spa | PROCEDURE FOR OXIDATION OF PARAFFINIC COMPOUNDS. |
US5304121A (en) | 1990-12-28 | 1994-04-19 | Boston Scientific Corporation | Drug delivery system making use of a hydrogel polymer coating |
DE3942872A1 (en) | 1989-12-23 | 1991-06-27 | Hoechst Ag | METHOD FOR THE ENANTIOSELECTIVE PRESENTATION OF ((OMEGA) -1) -HYDROXYALKYLXANTHINES |
US5112827A (en) * | 1990-05-18 | 1992-05-12 | Board Of Regents, The University Of Texas System | Drug to reverse fatty liver and atheromatous lesions |
WO1992007566A2 (en) | 1990-11-01 | 1992-05-14 | Board Of Regents, The University Of Texas System | Antifungal activity of and prevention of drug induced nephrotoxicity by methylxanthine analogues |
DE69119700T2 (en) | 1990-11-07 | 1996-11-07 | Hoechst Roussel Pharma | Use of xanthines in the manufacture of medicaments to inhibit the proliferation of human retroviruses |
IL100194A0 (en) | 1990-11-30 | 1992-08-18 | Hoechst Roussel Pharma | Use of xanthines for the preparation of a medicament effective for inhibiting the effects of allograft reaction in humans |
IL100195A0 (en) | 1990-11-30 | 1992-08-18 | Hoechst Roussel Pharma | Use of xanthines for the preparation of a medicament having immuno suppressing activity |
US5763446A (en) | 1992-03-26 | 1998-06-09 | University Of Southern California | Use of pentoxifylline and other tumor necrosis factor blockers for the treatment of aids-associated optic neuropathy and other central nervous system diseases |
US5780476A (en) * | 1992-11-16 | 1998-07-14 | Cell Therapeutics, Inc. | Hydroxyl-containing xanthine compounds |
US5716981A (en) | 1993-07-19 | 1998-02-10 | Angiogenesis Technologies, Inc. | Anti-angiogenic compositions and methods of use |
HUT68560A (en) | 1993-08-02 | 1995-04-27 | Chinoin Gyogyszer Es Vegyeszet | The use of xantine derivatives for promotion of healing of operative lesions |
ES2293638T3 (en) * | 1994-03-25 | 2008-03-16 | Isotechnika, Inc. | IMPROVEMENT OF THE EFFECTIVENESS OF PHARMACOS BY DEUTERATION. |
DE69528585D1 (en) | 1994-05-16 | 2002-11-21 | Cell Therapeutics Inc | ASYMMETRIC SYNTHESIS OF CHIRAL SECONDARY ALCOHOLS |
DE4430128A1 (en) | 1994-08-25 | 1996-02-29 | Hoechst Ag | Combination preparation with immunosuppressive, cardiovascular and cerebral effects |
WO1996005836A2 (en) | 1994-08-25 | 1996-02-29 | Medical University Of South Carolina | Methods of treating cold symptoms using pentoxifylline |
US6099562A (en) | 1996-06-13 | 2000-08-08 | Schneider (Usa) Inc. | Drug coating with topcoat |
DE19544768C1 (en) | 1995-11-30 | 1997-07-10 | Rentschler Arzneimittel | Use of a combination of pentoxifylline with type I interferons to treat multiple sclerosis |
US5985592A (en) | 1997-06-05 | 1999-11-16 | Dalhousie University | Uses for pentoxifylline or functional derivatives/metabolites thereof |
US6294350B1 (en) | 1997-06-05 | 2001-09-25 | Dalhousie University | Methods for treating fibroproliferative diseases |
US6248889B1 (en) | 1998-11-20 | 2001-06-19 | 3M Innovative Properties Company | Process for converting an alcohol to the corresponding fluoride |
US6417208B1 (en) | 1999-02-05 | 2002-07-09 | Albert Einstein College Of Medicine Of Yeshiva University | Method of identification of inhibitors of PDE1C |
GB9925962D0 (en) | 1999-11-02 | 1999-12-29 | Novartis Ag | Organic compounds |
GB0102107D0 (en) | 2001-01-26 | 2001-03-14 | Syngenta Ltd | Chemical process |
HU229938B1 (en) | 2001-05-03 | 2015-01-28 | Hoffmann La Roche | Pharmaceutical dosage form of amorphous nelfinavir mesylate |
JP2005503425A (en) | 2001-05-24 | 2005-02-03 | アレックザ モレキュラー デリヴァリー コーポレイション | Delivery of drug ester by the prescribed inhalation route |
WO2003013568A1 (en) | 2001-08-02 | 2003-02-20 | Ortho-Mcneil Pharmaceutical, Inc. | Cytokine modulation therapy |
IL161155A0 (en) | 2001-11-02 | 2004-08-31 | Pfizer Prod Inc | Treatment of insulin resistance syndrome and type 2 diabetes with pde9 inhibitors |
MXPA04008195A (en) | 2002-03-14 | 2004-11-26 | Bayer Pharmaceuticals Corp | Methods of treating diabetes using pde 11a inhibitors. |
DE10214228A1 (en) | 2002-03-22 | 2003-10-02 | Bdd Group Holding Ag Zug | Deuterated substituted indoles and medicinal products containing these compounds |
US20050107420A1 (en) * | 2002-05-23 | 2005-05-19 | Boehringe Ingelheim Pharma Gmbh & Co. Kg | Combination of a PDE4 inhibitor and tiotropium or derivative thereof for treating obstructive airways and other inflammatory diseases |
US20040220186A1 (en) | 2003-04-30 | 2004-11-04 | Pfizer Inc. | PDE9 inhibitors for treating type 2 diabetes,metabolic syndrome, and cardiovascular disease |
JP2009513494A (en) | 2003-06-30 | 2009-04-02 | ニコメッド ゲゼルシャフト ミット ベシュレンクテル ハフツング | Pyrrodihydroisoquinoline as a PDE10 inhibitor |
WO2005012485A2 (en) | 2003-07-31 | 2005-02-10 | Bayer Pharmaceuticals Corporation | Methods for treating diabetes and related disorders using pde10a inhibitors |
WO2005023193A2 (en) | 2003-09-04 | 2005-03-17 | Interleukin Genetics, Inc. | Methods of treating endometriosis |
MXPA06014236A (en) | 2004-06-07 | 2007-02-14 | Pfizer Prod Inc | Phosphodiesterase 10 inhibition as treatment for obesity-related and metabolic syndrome-related conditions. |
US20080020018A1 (en) | 2004-09-27 | 2008-01-24 | Joey Moodley | Combination Products |
JP2008514706A (en) | 2004-09-29 | 2008-05-08 | コーディス・コーポレイション | Pharmaceutical dosage forms of stable amorphous rapamycin-like compounds |
EP1934201A1 (en) | 2005-10-06 | 2008-06-25 | Auspex Pharmaceuticals Inc. | Deuterated inhibitors of gastric h+, k+-atpase with enhanced therapeutic properties |
JP5292413B2 (en) * | 2008-02-29 | 2013-09-18 | コンサート ファーマシューティカルズ インコーポレイテッド | Substituted xanthine derivatives |
-
2010
- 2010-09-01 US US12/873,991 patent/US20110053961A1/en not_active Abandoned
- 2010-09-02 KR KR1020127008446A patent/KR101591137B1/en active Active
- 2010-09-02 EA EA201270339A patent/EA023809B1/en not_active IP Right Cessation
- 2010-09-02 BR BR112012008108A patent/BR112012008108B1/en active IP Right Grant
- 2010-09-02 ES ES10814504.6T patent/ES2542401T3/en active Active
- 2010-09-02 ME MEP-2015-108A patent/ME02177B/en unknown
- 2010-09-02 EP EP20100814504 patent/EP2473053B1/en active Active
- 2010-09-02 PH PH1/2012/500278A patent/PH12012500278A1/en unknown
- 2010-09-02 AU AU2010289465A patent/AU2010289465B2/en active Active
- 2010-09-02 JP JP2012528054A patent/JP5292516B2/en active Active
- 2010-09-02 MX MX2012002705A patent/MX2012002705A/en active IP Right Grant
- 2010-09-02 HR HRP20150797TT patent/HRP20150797T1/en unknown
- 2010-09-02 CN CN201080039090.5A patent/CN102480968B/en active Active
- 2010-09-02 HU HUE10814504A patent/HUE026800T2/en unknown
- 2010-09-02 CA CA2771123A patent/CA2771123C/en active Active
- 2010-09-02 DK DK10814504.6T patent/DK2473053T3/en active
- 2010-09-02 EP EP15163741.0A patent/EP2963040A1/en not_active Withdrawn
- 2010-09-02 CN CN201410746544.2A patent/CN104478881A/en active Pending
- 2010-09-02 PL PL10814504T patent/PL2473053T3/en unknown
- 2010-09-02 WO PCT/US2010/047708 patent/WO2011028922A1/en active Application Filing
- 2010-09-02 PT PT108145046T patent/PT2473053E/en unknown
- 2010-09-02 SI SI201030985T patent/SI2473053T1/en unknown
- 2010-09-02 IN IN1641DEN2012 patent/IN2012DN01641A/en unknown
-
2012
- 2012-02-21 ZA ZA2012/01295A patent/ZA201201295B/en unknown
Also Published As
Publication number | Publication date |
---|---|
JP5292516B2 (en) | 2013-09-18 |
KR20120050509A (en) | 2012-05-18 |
EP2473053B1 (en) | 2015-04-22 |
DK2473053T3 (en) | 2015-07-27 |
CA2771123A1 (en) | 2011-03-10 |
EA023809B1 (en) | 2016-07-29 |
HK1170377A1 (en) | 2013-03-01 |
PT2473053E (en) | 2015-09-14 |
WO2011028922A1 (en) | 2011-03-10 |
SI2473053T1 (en) | 2015-10-30 |
CA2771123C (en) | 2017-11-14 |
MX2012002705A (en) | 2012-04-02 |
US20110053961A1 (en) | 2011-03-03 |
PH12012500278A1 (en) | 2012-10-22 |
HUE026800T2 (en) | 2016-07-28 |
EP2473053A4 (en) | 2013-03-27 |
EP2963040A1 (en) | 2016-01-06 |
ES2542401T3 (en) | 2015-08-05 |
AU2010289465B2 (en) | 2016-03-10 |
ME02177B (en) | 2015-10-20 |
BR112012008108A2 (en) | 2015-09-22 |
CN102480968A (en) | 2012-05-30 |
KR101591137B1 (en) | 2016-02-02 |
CN102480968B (en) | 2015-01-07 |
AU2010289465A1 (en) | 2012-03-01 |
JP2013503894A (en) | 2013-02-04 |
HRP20150797T1 (en) | 2015-09-11 |
ZA201201295B (en) | 2012-10-31 |
PL2473053T3 (en) | 2015-10-30 |
BR112012008108B1 (en) | 2019-10-22 |
CN104478881A (en) | 2015-04-01 |
EA201270339A1 (en) | 2012-09-28 |
EP2473053A1 (en) | 2012-07-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IN2012DN01641A (en) | ||
WO2009108383A3 (en) | Substituted xanthine derivatives | |
IN2012DN01642A (en) | ||
CA2871471C (en) | Dna-pk inhibitors | |
MX2009008253A (en) | Kinase inhibitors. | |
MX2012000709A (en) | Pyrrolopyridine inhibitors of kinases. | |
MX2009009590A (en) | Aminopyrimidines useful as inhibitors of protein kinases. | |
IL200793A0 (en) | Aminopyrimidines, compositions comprising the same and use thereof for inhibiting protein kinases | |
MX365294B (en) | Dna-pk inhibitors. | |
MX2009010037A (en) | Aminopyrimidines useful as kinase inhibitors. | |
MD4820B1 (en) | Substituted dihydroisoquinolinone compounds | |
MX2011009796A (en) | Inhibitors of pi3 kinase. | |
UA110197C2 (en) | To novel compounds which are effective as an inhibitor for xanthine oxidase, a process for preparing the same, and a pharmaceutical composition comprising a therapeutically effective amount of the same | |
MX350761B (en) | Isoindolinone inhibitors of phosphatidylinositol 3-kinase. | |
MX2009009592A (en) | Aminopyridines useful as inhibitors of protein kinases. | |
TN2014000016A1 (en) | 4 - piperidinyl compounds for use as tankyrase inhibitors | |
MX2011013032A (en) | Inhibitors of phosphatidylinositol 3-kinase. | |
MX2009011811A (en) | Aminopyrimidines useful as kinase inhibitors. | |
MX2009000169A (en) | Purinone derivatives as hm74a agonists. | |
MX2012001134A (en) | Compositions and methods for inhibition of the jak pathway. | |
JO2682B1 (en) | 7-ALkynyl-1,8-Naphthyridone Derivatives, Preparation Thereof And Therapeutic Use Thereof | |
NZ727188A (en) | Aldosterone synthase inhibitors | |
MX2011008645A (en) | Tetrahydrothiazolopyridine inhibitors of phosphatidylinositol 3-kinase. | |
WO2013155465A8 (en) | Substituted xanthine derivatives | |
MX2011012524A (en) | Inhibitors of c-met protein kinase. |